Bevacizumab Concentrate For Solution For Infusion

Product Description

Bevacizumab concentrate for solution for infusion, with a strength of 400 mg/16 mL, is a medication used in the treatment of various types of cancer. Here's an overview of its use:

1. Colorectal Cancer Bevacizumab is approved for use in combination with chemotherapy for the treatment of metastatic colorectal cancer (CRC). It is typically used in combination with a fluoropyrimidine-based chemotherapy regimen (such as FOLFOX or FOLFIRI).

2. Lung Cancer Bevacizumab is also used in the treatment of non-small cell lung cancer (NSCLC), specifically in combination with chemotherapy for the treatment of advanced, metastatic, or recurrent NSCLC. It may be used in patients who have not received prior chemotherapy for metastatic disease.

3. Breast Cancer Bevacizumab may be used in combination with chemotherapy for the treatment of metastatic breast cancer, particularly in cases where the cancer is HER2-negative.

4. Renal Cell Carcinoma Bevacizumab, in combination with interferon alfa, is used for the treatment of metastatic renal cell carcinoma (kidney cancer).

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a protein involved in the formation of new blood vessels that supply tumors with oxygen and nutrients. By inhibiting VEGF, bevacizumab helps to disrupt the blood supply to tumors, thereby slowing their growth and reducing their ability to spread.

The concentration of 400 mg/16 mL indicates that each mL of the solution contains 25 mg of bevacizumab. This solution is typically diluted further and administered as an intravenous infusion over a period of time specified by a healthcare professional.

Common side effects of bevacizumab may include hypertension (high blood pressure), proteinuria (protein in the urine), bleeding, gastrointestinal perforation, impaired wound healing, and increased risk of blood clots. It's important for patients to be monitored closely by their healthcare provider while receiving bevacizumab to manage any side effects and ensure the treatment remains effective.

As with any cancer treatment, it's crucial to discuss the potential benefits and risks with a healthcare professional to make informed decisions about treatment options.

How to Use Bevacizumab Concentrate Safely

Bevacizumab must be diluted with 0.9% sodium chloride and administered as an intravenous infusion over a minimum of 90 minutes for the first dose. If tolerated, subsequent infusions may take 60 or even 30 minutes. Do not give as an IV push or bolus, and avoid mixing with dextrose solutions. Administration should occur in a hospital or clinical setting by qualified healthcare professionals.


What to Monitor During Treatment

Patients receiving Bevacizumab should be closely monitored for potential infusion reactions, hypertension, thromboembolic events, and proteinuria. Regular assessments will help ensure treatment tolerability and patient safety. Any side effects or unusual symptoms should be reported to the attending medical team promptly.


Benefits and Indications of Bevacizumab

Bevacizumab offers significant benefits for individuals with various cancers, such as colorectal, non-small cell lung, glioblastoma, renal cell carcinoma, cervical, and ovarian cancer. By inhibiting vascular endothelial growth factor (VEGF), it helps slow tumor growth and progression, thus improving therapeutic outcomes in eligible patients.